These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 31375174)

  • 1. Cervical, Ovarian and Endometrial Tumor Markers: Potential Clinical Value.
    Malhone C; Longatto-Filho A
    Semin Ultrasound CT MR; 2019 Aug; 40(4):350-357. PubMed ID: 31375174
    [TBL] [Abstract][Full Text] [Related]  

  • 2. p16 expression in the female genital tract and its value in diagnosis.
    O'Neill CJ; McCluggage WG
    Adv Anat Pathol; 2006 Jan; 13(1):8-15. PubMed ID: 16462152
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alteration of p16 and p15 genes in human uterine tumours.
    Nakashima R; Fujita M; Enomoto T; Haba T; Yoshino K; Wada H; Kurachi H; Sasaki M; Wakasa K; Inoue M; Buzard G; Murata Y
    Br J Cancer; 1999 May; 80(3-4):458-67. PubMed ID: 10408854
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biological markers with potential clinical value in endometrial cancer - review of the literature.
    Taoussi N; Alghamdi A; Futyma K; Rechberger T
    Ginekol Pol; 2017; 88(6):331-336. PubMed ID: 28727134
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endocervical adenocarcinomas with prominent endometrial or endomyometrial involvement simulating primary endometrial carcinomas: utility of HPV DNA detection and immunohistochemical expression of p16 and hormone receptors to confirm the cervical origin of the corpus tumor.
    Yemelyanova A; Vang R; Seidman JD; Gravitt PE; Ronnett BM
    Am J Surg Pathol; 2009 Jun; 33(6):914-24. PubMed ID: 19295407
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predicting Lymph Node Metastasis in Endometrial Cancer Using Serum CA125 Combined with Immunohistochemical Markers PR and Ki67, and a Comparison with Other Prediction Models.
    Yang B; Shan B; Xue X; Wang H; Shan W; Ning C; Zhou Q; Chen X; Luo X
    PLoS One; 2016; 11(5):e0155145. PubMed ID: 27163153
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The feasibility of detecting endometrial and ovarian cancer using DNA methylation biomarkers in cervical scrapings.
    Chang CC; Wang HC; Liao YP; Chen YC; Weng YC; Yu MH; Lai HC
    J Gynecol Oncol; 2018 Jan; 29(1):e17. PubMed ID: 29185275
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Utility of ProExC and IMP3 immunocytochemical staining in atypical glandular cells of undetermined significance in liquid-based cervical cytology.
    Lastra RR; Ou JJ; Reilly ME; Lawrence WD; Baloch ZW; Brooks JS; Barroeta JE
    Diagn Cytopathol; 2014 May; 42(5):375-9. PubMed ID: 23904388
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cervical cancer: Biomarkers for diagnosis and treatment.
    Dasari S; Wudayagiri R; Valluru L
    Clin Chim Acta; 2015 May; 445():7-11. PubMed ID: 25773118
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Tumor markers useful in the diagnostics and monitoring of endometrial and cervical cancer].
    Bedkowska GE; Lawicki S; Szmitkowski M
    Postepy Hig Med Dosw (Online); 2007; 61():122-8. PubMed ID: 17369780
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Personalized Circulating Tumor DNA Biomarkers Dynamically Predict Treatment Response and Survival In Gynecologic Cancers.
    Pereira E; Camacho-Vanegas O; Anand S; Sebra R; Catalina Camacho S; Garnar-Wortzel L; Nair N; Moshier E; Wooten M; Uzilov A; Chen R; Prasad-Hayes M; Zakashansky K; Beddoe AM; Schadt E; Dottino P; Martignetti JA
    PLoS One; 2015; 10(12):e0145754. PubMed ID: 26717006
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Viral-Cellular DNA Junctions as Molecular Markers for Assessing Intra-Tumor Heterogeneity in Cervical Cancer and for the Detection of Circulating Tumor DNA.
    Carow K; Gölitz M; Wolf M; Häfner N; Jansen L; Hoyer H; Schwarz E; Runnebaum IB; Dürst M
    Int J Mol Sci; 2017 Sep; 18(10):. PubMed ID: 28937589
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Metastatic mechanisms of uterine malignancies and therapeutic consequences].
    Lax SF; Tamussino KF; Lang PF
    Pathologe; 2016 Nov; 37(6):549-556. PubMed ID: 27757531
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Strategies for phase II cancer chemoprevention trials: cervix, endometrium, and ovary.
    Kelloff GJ; Boone CW; Crowell JA; Nayfield SG; Hawk E; Steele VE; Lubet RA; Sigman CC
    J Cell Biochem Suppl; 1995; 23():1-9. PubMed ID: 8747372
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence of microsatellite instability in synchronous tumors of the ovary and endometrium.
    Shannon C; Kirk J; Barnetson R; Evans J; Schnitzler M; Quinn M; Hacker N; Crandon A; Harnett P
    Clin Cancer Res; 2003 Apr; 9(4):1387-92. PubMed ID: 12684409
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantitation of Fas and Fas ligand gene expression in human ovarian, cervical and endometrial carcinomas using real-time quantitative RT-PCR.
    Das H; Koizumi T; Sugimoto T; Chakraborty S; Ichimura T; Hasegawa K; Nishimura R
    Br J Cancer; 2000 May; 82(10):1682-8. PubMed ID: 10817504
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The high frequency of de novo promoter methylation in synchronous primary endometrial and ovarian carcinomas.
    Furlan D; Carnevali I; Marcomini B; Cerutti R; Dainese E; Capella C; Riva C
    Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3329-36. PubMed ID: 16740754
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Small non-coding RNA deregulation in endometrial carcinogenesis.
    Ravo M; Cordella A; Rinaldi A; Bruno G; Alexandrova E; Saggese P; Nassa G; Giurato G; Tarallo R; Marchese G; Rizzo F; Stellato C; Biancardi R; Troisi J; Di Spiezio Sardo A; Zullo F; Weisz A; Guida M
    Oncotarget; 2015 Mar; 6(7):4677-91. PubMed ID: 25686835
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Consistent absence of BRAF mutations in cervical and endometrial cancer despite KRAS mutation status.
    Pappa KI; Choleza M; Markaki S; Giannikaki E; Kyroudi A; Vlachos G; Voulgaris Z; Anagnou NP
    Gynecol Oncol; 2006 Mar; 100(3):596-600. PubMed ID: 16256179
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Loss of nuclear p16 protein expression is not associated with promoter methylation but defines a subgroup of aggressive endometrial carcinomas with poor prognosis.
    Salvesen HB; Das S; Akslen LA
    Clin Cancer Res; 2000 Jan; 6(1):153-9. PubMed ID: 10656444
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.